BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sicurella M, Nicoli F, Gallerani E, Volpi I, Berto E, Finessi V, Destro F, Manservigi R, Cafaro A, Ensoli B, Caputo A, Gavioli R, Marconi PC. An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge. PLoS One 2014;9:e100844. [PMID: 25033084 DOI: 10.1371/journal.pone.0100844] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Nicoli F, Mantelli B, Gallerani E, Telatin V, Squarzon L, Masiero S, Gavioli R, Palù G, Barzon L, Caputo A. Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine. NPJ Vaccines 2022;7:37. [PMID: 35292655 DOI: 10.1038/s41541-022-00458-0] [Reference Citation Analysis]
2 Ensoli B, Moretti S, Borsetti A, Maggiorella MT, Buttò S, Picconi O, Tripiciano A, Sgadari C, Monini P, Cafaro A. New insights into pathogenesis point to HIV-1 Tat as a key vaccine target. Arch Virol 2021. [PMID: 34390393 DOI: 10.1007/s00705-021-05158-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Rider PJ, Dulin H, Uche IK, Mcgee MC, Breitenstein B, Tan GS, Huang W, Kousoulas KG, Hai R. A Herpes Simplex Virus Type-1-derived influenza vaccine induces balanced adaptive immune responses and protects mice from lethal influenza virus challenge.. [DOI: 10.1101/2021.08.05.455241] [Reference Citation Analysis]
4 Nicoli F, Pacifico S, Gallerani E, Marzola E, Albanese V, Finessi V, Llewellyn-Lacey S, Price DA, Appay V, Marconi P, Guerrini R, Caputo A, Gavioli R. Use of a Novel Peptide Welding Technology Platform for the Development of B- and T-Cell Epitope-Based Vaccines. Vaccines (Basel) 2021;9:526. [PMID: 34069535 DOI: 10.3390/vaccines9050526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhou X, Chen X, Hong T, Zhang M, Cai Y, Cui L. TTC3-Mediated Protein Quality Control, A Potential Mechanism for Cognitive Impairment. Cell Mol Neurobiol 2021. [PMID: 33638766 DOI: 10.1007/s10571-021-01060-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Nicoli F, Gallerani E, Sicurella M, Pacifico S, Cafaro A, Ensoli B, Marconi P, Caputo A, Gavioli R. The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation. Vaccines (Basel) 2020;8:E274. [PMID: 32512757 DOI: 10.3390/vaccines8020274] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Moretti S, Cafaro A, Tripiciano A, Picconi O, Buttò S, Ensoli F, Sgadari C, Monini P, Ensoli B. HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy. Expert Rev Vaccines 2020;19:71-84. [PMID: 31957513 DOI: 10.1080/14760584.2020.1712199] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
8 Nicoli F, Mantelli B, Gallerani E, Telatin V, Bonazzi I, Marconi P, Gavioli R, Gabrielli L, Lazzarotto T, Barzon L, Palù G, Caputo AA. HPV-Specific Systemic Antibody Responses and Memory B Cells are Independently Maintained up to 6 Years and in a Vaccine-Specific Manner Following Immunization with Cervarix and Gardasil in Adolescent and Young Adult Women in Vaccination Programs in Italy. Vaccines (Basel) 2020;8:E26. [PMID: 31947611 DOI: 10.3390/vaccines8010026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
9 Xu X, Zhang Y, Li Q. Characteristics of herpes simplex virus infection and pathogenesis suggest a strategy for vaccine development. Rev Med Virol 2019;29:e2054. [PMID: 31197909 DOI: 10.1002/rmv.2054] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
10 Nicoli F, Gallerani E, Sforza F, Finessi V, Chachage M, Geldmacher C, Cafaro A, Ensoli B, Caputo A, Gavioli R. The HIV-1 Tat protein affects human CD4+ T-cell programing and activation, and favors the differentiation of naïve CD4+ T cells. AIDS 2018;32:575-81. [PMID: 29280760 DOI: 10.1097/QAD.0000000000001734] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
11 Tomusange K, Wijesundara D, Gummow J, Wesselingh S, Suhrbier A, Gowans EJ, Grubor-Bauk B. Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses. Sci Rep 2016;6:36658. [PMID: 27853256 DOI: 10.1038/srep36658] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
12 Nicoli F, Gallerani E, Skarlis C, Sicurella M, Cafaro A, Ensoli B, Caputo A, Marconi PC, Gavioli R. Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection. Vaccine 2016;34:2216-24. [PMID: 27002499 DOI: 10.1016/j.vaccine.2016.03.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
13 Stanfield B, Kousoulas KG. Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections. Curr Clin Microbiol Rep 2015;2:125-36. [PMID: 27114893 DOI: 10.1007/s40588-015-0020-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
14 Nicoli F, Sforza F, Gavioli R. Different expression of Blimp-1 in HIV infection may be used to monitor disease progression and provide a clue to reduce immune activation and viral reservoirs. AIDS 2015;29:133-4. [PMID: 25562499 DOI: 10.1097/QAD.0000000000000514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]